Recent advances in systemic therapy for advanced endometrial cancer

Current Opinion in Oncology

Volumn 23, Issue 5, 2011, Pages 494-500

  Tsoref, Daliah ^a   Oza, Amit M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Advanced endometrial cancer; novel targeted agents; systemic therapy

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPOTHILONE DERIVATIVE; EVEROLIMUS; GEFITINIB; GEMCITABINE; GESTAGEN; GONADORELIN ANTAGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IROSUSTAT; IXABEPILONE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM; RIDAFOROLIMUS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; ENDOMETRIUM CANCER; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 80052023017     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328348840a     Document Type: Article

References (62)

1. American Cancer Society. Estimated new cancer cases and deaths by sex for all sites, US. 2010. http://www.cancer.org/acs/groups/content/@nho/docu ments/document/acspc-024113.pdf page 4.
2. Bokhman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol 1983; 15:7-10.
3. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16:8-13.
4. Sabbatini PJ, Alektiar KM, Barakat RR, et al. Handbook of gynecologic oncology. 2nd ed. London: Martin Dunitz; 2001:; pp. 265-278.
5. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers: evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000; 74:357-364. (Pubitemid 32126247)
6. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systemic review. Int J Gynecol cancer 2007; 17:964-978. (Pubitemid 47414814)
7. Ma BB, Oza A, Eisenhauer E, et al. The activity of Letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers: a study of the 18 National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14:650-658. (Pubitemid 39062922)
8. Thigpen JT, BradyMF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17:1736-1744. (Pubitemid 29269242)
9. Whitney CW, Brunetto MF, Homesley HD, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:4-9. (Pubitemid 38147364)
10. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:10-14. (Pubitemid 38147365)
11. Rose PG, Brunetto VL, Vante L, et al. A phase II trial of Anastrozole in advanced recurrent of persistent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2000; 78:212-216. (Pubitemid 30650356)
12. Kokka F, Brockbank E, OramD, et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010:CD007926.
13. Reed MJ, Purohit A, Woo LWL, et al. Steroid sulfatase: molecular biology, regulation and inhibition. Endocr Rev 2005; 26:171-202.
14. Falany JL, Macrina N, Falany CN. Regulation of MCF-7 breast cancer cell growth by b-estradiol sulfonation. Breast Cancer Res Treat 2002; 74:167-176. (Pubitemid 34816222)
15. Utsunomiya H, Ito K, Suzuki T, et al. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 2004; 10:5850-5856. (Pubitemid 39180965)
16. Foster PA, Lawrence Woo LW, Barry VL, et al. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 2008; 149:4035-4042.
17. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25:2983-2990. (Pubitemid 47123163)
18. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of Doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22:3902-3908. (Pubitemid 41079871)
19. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomized study (55872) by the EORTC Gynecological Cancer Group. Ann Oncol 2003; 14:441-448. (Pubitemid 36367423)
20. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatinum with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22:2159-2166. (Pubitemid 41095150)
21. Hoskins PJ, Swenerton KD, Pike A, et al. Paclitaxel and Carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19:4048-4053. (Pubitemid 32976691)
22. Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther 2009; 9:905-916.
23. Miller DS, Blessing AJ, Drake RD, et al. A phase II evaluation of pemetrexed in the treatment of recurrent of persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009; 115:443-446.
24. Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine in the treatment of recurrent or persistent endometrial carcinoma: a gynaecologic oncology group study. Gynecol Oncol 2011; 121:118-121. doi: 10.1016/j.ygyno.2010.11.027.
25. Brown J, Smith JA, Lois M, et al. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma. Cancer 2010; 116:4973-4979.
26. Ito K, Tsubamoto H, Itani Y, et al. A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecol Oncol 2011; 120:193-197.
27. Dizon Ds, Blessing JA, McMeekin S, et al. Phase II Trial of Ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009; 27:3104-3108.
28. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945. (Pubitemid 39071573)
29. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer Control 2009; 16:8-13.
30. Oza AM, Elit L, Biagni J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. J Clin Oncol 2006; 24:3003.
31. Oza AM, Elit L, Provencher D. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008; 26:5516.
32. Kollmannsberger C, Hirte H, Siu LL, et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCICCTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 2011. doi: 10.1093/annonc/mdr063. [Epub ahead of print]
33. Temkin S, Yamada S, Fleming G. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynaecologic malignancies. Gynecol Oncol 2010; 117:473-476.
34. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 2007; 25 (Suppl 18S):5516.
35. Slomovitz B, Lu K, Johnston T, et al. A phase II study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010; 116:5415-5419.
36. Samaranthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; 2010:162363.
37. Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22:522-529.
38. Jimeno A, Hong DS, Hecker S, et al. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI3K) inhibitor [abstract]. J Clin Oncol 2009; (Suppl 156S):3542.
39. Shapiro G, Kwak E, Beselga J, et al. Phase I dose escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumours [abstract]. J Clin Oncol 2009; 27 (Suppl 146S):3500.
40. Baselga J, De Jonge M, Rodon J, et al. A first in human phase I study of BKM120 an oral pan-class PI3K inhibitor, in patients with advanced solid tumours [abstract]. J Clin Oncol 2010; 28 (Suppl 15S):3003.
41. Wagner AJ, Von Hoff DH, LoRusso PM, et al. A first in human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours [abstract]. J Clin Oncol 2009; 27 (Suppl 146S):3501.
42. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075-1083.
43. Feldman ME, Apsel B, Uotila A, et al. Active site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7:e38.
44. LoRusso P, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765 a PI3K/TORC1/TORC2 inhibitor administered orally to patient with advanced solid tumours [abstract]. J Clin Oncol 2009; 27 (Suppl 146S):3502.
45. Dobrzycka B, Terlikowski SJ, Kwiatkiwski M. Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Gineklo Pol 2010; 81:422-425.
46. Kamat AA, Merritt WM, Coffey D. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13:7487-7495.
47. Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007; 27:3525-3528. (Pubitemid 47607497)
48. Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer. A gynaecologic oncology group study. J Clin Oncol 2009; 27:5531.
49. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117:37-40.
50. Correa R, Mackay H, Hirte H, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH, U Chicago, and California Cancer Phase II Consortia. JCO 2010; 28:5038.
51. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2:53ra75.
52. Forster MD, Dedes KJ, Sandhu S, et al. Treatment with Olaparib in a patient with PTEN deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011; 8:302-306. doi:10.1038/nrclinonc.2011.42.
53. De Luca A, Carotenuto A, Rachiglio A, et al. The role of EGFR signalling in tumor microenvironment. J Cell Physiol 2008; 214:559-567. (Pubitemid 351224199)
54. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her-2 positive breast cancer. N Engl J Med 2005; 353:165-172.
55. Lievre A, Bachatte J-B, Blige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379. (Pubitemid 351171687)
56. Takahashi K, Saga Y, Mizukami H, et al. Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. Int J Oncol 2009; 35:725-729.
57. Leslie KK, SillMW, Darcy KM, et al. Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in Gynecologic Oncology Group phase II trial of persistent of recurrent endometrial cancer [abstract]. J Clin Oncol 2009; 27 (Suppl 15S):A-e16542.
58. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008; 26:4319-4325.
59. Santin A, Bellone S, Roman J, et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma over-expressing Her2-neu. Int J Gyn Obst 2008; 102:128-131.
60. Fleming G, Sill M, Darcy K, et al. Phase II trial of Trastuzumab in women with advanced or recurrent, Her2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116:15-20.
61. Slomovitz BM, Broaddus RR, Schmandt R, et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 2004; 95:32-36. (Pubitemid 39286274)
62. Slomovitz BM, Ramondetta LM, Johnston T, et al. A phase I study of imatinib mesylate and paclitaxel in patients with advanced (stage IIIc/IV) or recurrent uterine papillary serous carcinoma (UPSC) [abstract]. J Clin Oncol 2007; 25 (Suppl 18S):16025.